Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD5 | Q86SK9 | 8/20 | 0.56 |
| ▸ | SCD | O00767 | 3/20 | 0.56 |
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.42 |
| ▸ | CPT2 | P23786 | 2/20 | 0.41 |
| ▸ | CPT1A | P50416 | 2/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2899238 | 1.00 | SCD5 (0.56) | SCD5SCDUSP30HCRTR1HCRTR2 | |
| SCHEMBL4076414 | 0.97 | SCD5 (0.53) | SCD5SCDUSP30HCRTR1HCRTR2 | |
| SCHEMBL5630003 | 0.97 | SCD5 (0.53) | SCD5SCDUSP30HCRTR1HCRTR2 | |
| SCHEMBL13412244 | 0.86 | HCRTR1 (0.51) | SCD5SCDHCRTR1HCRTR2 | |
| SCHEMBL2896726 | 0.86 | HCRTR1 (0.51) | SCD5SCDHCRTR1HCRTR2 | |
| SCHEMBL3974945 | 0.86 | HCRTR1 (0.54) | SCD5SCDHCRTR1HCRTR2 | |
| SCHEMBL5478785 | 0.85 | SMN1; SMN2 (0.48) | USP30HCRTR1HCRTR2 | |
| SCHEMBL8226950 | 0.85 | HCRTR1 (0.44) | SCD5SCDUSP30HCRTR1HCRTR2 | |
| SCHEMBL2890825 | 0.85 | GRM5 (0.46) | SCD5HCRTR1HCRTR2 | |
| SCHEMBL13412243 | 0.85 | GRM5 (0.46) | SCD5HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2032568-A2 | POLYCYCLIC HETEROCYCLIC COMPOUNDS AND THEIR USE AS MODULATORS OF THE METABOTROPIC GLUTAMATE 5 RECEPTOR | AstraZeneca AB (SE) | 2009-03-11 | — | — | EP | claimed |
| WO-2007130823-A2 | POLYCYCLIC HETEROCYCLIC COMPOUNDS AND THEIR USE AS MODULATORS OF THE METABOTROPIC GLUTAMATE 5 RECEPTOR | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | claimed |
| US-20070259923-A1 | MGluR5 modulators IV | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| US-20070259923-A1 | MGluR5 modulators IV | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259923-A1 | MGluR5 modulators IV | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259923-A1 | MGluR5 modulators IV | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259923-A1 | MGluR5 modulators IV | GRM5, GRM4, GRIK5 | SCD5 412/4885SCD 1643/4885USP30 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.